Literature DB >> 6699099

Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans.

R A Majack, A W Clowes.   

Abstract

Previous studies have suggested that heparin-like glycosaminoglycans may be endogenous inhibitors of smooth muscle proliferation in the vessel wall. The purpose of this study was to determine the effects of exogenous glycosaminoglycans on rat vascular (aortic) smooth muscle cell migration following wounding in vitro. Our data indicate that heparin and related molecules (iota carrageenan, dextran sulfate), but not other glycosaminoglycans (hyaluronate, chondroitin, and dermatan sulfates), inhibit smooth muscle cell motility in a cell-specific, dose-dependent, and reversible fashion. The effect of heparin was maximal (60% inhibition) at 10 micrograms/ml; a half-maximal effect was observed at 1 microgram/ml. Heparin did not significantly affect the migration of bovine aortic endothelium or Swiss 3T3 cells. These observations support the concept that heparin-like glycosaminoglycans may be important regulators of vascular smooth muscle cell function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6699099     DOI: 10.1002/jcp.1041180306

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  51 in total

1.  Heparin/endothelial cell growth supplement regulates matrix gene expression and prolongs life span of vascular smooth muscle cells through modulation of interleukin-1.

Authors:  J Y Hsu; M Y Hsu; T Sorger; M Herlyn; E M Levine
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Nov-Dec       Impact factor: 2.416

2.  Imaging of homeostatic, neoplastic, and injured tissues by HA-based probes.

Authors:  Mandana Veiseh; Daniel Breadner; Jenny Ma; Natalia Akentieva; Rashmin C Savani; Rene Harrison; David Mikilus; Lisa Collis; Stefan Gustafson; Ting-Yim Lee; James Koropatnick; Leonard G Luyt; Mina J Bissell; Eva A Turley
Journal:  Biomacromolecules       Date:  2011-12-12       Impact factor: 6.988

3.  Cinematographic analysis of vascular smooth muscle cell interactions with extracellular matrix.

Authors:  M Absher; L Baldor
Journal:  In Vitro Cell Dev Biol       Date:  1991-01

4.  Deposition of extracellular matrix along the pathways of migrating fibroblasts.

Authors:  W Halfter; D Liverani; M Vigny; D Monard
Journal:  Cell Tissue Res       Date:  1990-12       Impact factor: 5.249

5.  Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesion.

Authors:  Kristin L Reigle; Gloria Di Lullo; Kevin R Turner; Jerold A Last; Inna Chervoneva; David E Birk; James L Funderburgh; Elizabeth Elrod; Markus W Germann; Charles Surber; Ralph D Sanderson; James D San Antonio
Journal:  J Cell Biochem       Date:  2008-08-01       Impact factor: 4.429

6.  Human smooth muscle cells of the aorta and vena cava: different sensitivity to the inhibition of proliferation by heparin in vitro.

Authors:  D G Thilo-Körner; R H Bödeker
Journal:  Klin Wochenschr       Date:  1985-08-01

7.  Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells.

Authors:  R D Kenagy; S T Nikkari; H G Welgus; A W Clowes
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

8.  Evidence for prostacyclin and cAMP upregulation by bradykinin and insulin-like growth factor 1 in vascular smooth muscle cells.

Authors:  Jerry G Webb; Yan Tan; Miran A Jaffa; Ayad A Jaffa
Journal:  J Recept Signal Transduct Res       Date:  2010-04       Impact factor: 2.092

9.  The effect of pancreatopeptidase E (elastase) on anastomotic intimal thickness in two types of vascular prosthesis.

Authors:  F Akimoto
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

10.  Human arterial smooth muscle cells in culture: inverse relationship between proliferation and expression of contractile proteins.

Authors:  G Fager; G K Hansson; A M Gown; D M Larson; O Skalli; G Bondjers
Journal:  In Vitro Cell Dev Biol       Date:  1989-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.